×

Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England

  • Author

    Shakir SA Wilton L Harris S urich-Barrera B

    Shakir SA Wilton L Harris S urich-Barrera B

  • Cite

    Drug Saf. 2006;29(2):151-60

Under-reporting of adverse drug reactions : a systematic review

  • Author

    Shakir SA Hazell L

    Shakir SA Hazell L

  • Cite

    Drug Saf. 2006;29(5):385-96.

Bill Inman: drug safety physician and pharmacoepidemiologist

  • Author

    Shakir SA

    Shakir SA

  • Cite

    Drug Saf. 2006;29(3):187-8

Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England

  • Author

    Layton D Shakir SA Cornelius V Wilton L Boshier A Harris S

    Layton D Shakir SA Cornelius V Wilton L Boshier A Harris S

  • Cite

    Drug Saf. 2006;29(10):897-909

Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England

  • Author

    Shakir SA Wilton L Harris S Barrera BA

    Shakir SA Wilton L Harris S Barrera BA

  • Cite

    Osteoporos Int. 2005 Dec;16(12):1989-98

Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia

  • Author

    Layton D Shakir SA Wilton LV Harris S

    Layton D Shakir SA Wilton LV Harris S

  • Cite

    J Psychopharmacol. 2005 Sep;19(5):473-82

Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin

  • Author

    Layton D Shakir SA Wilton LV Pearce HM

    Layton D Shakir SA Wilton LV Pearce HM

  • Cite

    Br J Clin Pharmacol. 2005 Jul;60(1):98-102

The negative effect of red tape on research

  • Author

    Camm AJ Shakir SA Boshier A Telfer P Behr E Pakrashi T

    Camm AJ Shakir SA Boshier A Telfer P Behr E Pakrashi T

  • Cite

    Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):373-6

Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study

  • Author

    Layton D Shakir SA Wilton LV Clarke A

    Layton D Shakir SA Wilton LV Clarke A

  • Cite

    Osteoporos Int. 2005 May;16(5):490-500

The safety and effectiveness of newer antiepileptics: A comparative postmarketing cohort study

  • Author

    Shakir SAW Acharya NV Pickering RM Wilton LW

    Shakir SAW Acharya NV Pickering RM Wilton LW

  • Cite

    J Clin Pharmacol. 2005 Apr;45(4):385-93

Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative stud

  • Author

    Shakir S Wilton L Koren G av-Citrin O Einarson A McKenna K Tetelbaum M Levinson A Zipursky RB

    Shakir S Wilton L Koren G av-Citrin O Einarson A McKenna K Tetelbaum M Levinson A Zipursky RB

  • Cite

    J Clin Psychiatry. 2005 Apr;66(4):444-9

Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study

  • Author

    Shakir S Boshier A Koren G Einarson A Chun-Fai-Chan B Fayez I Kalra S Voyer-Lavigne S

    Shakir S Boshier A Koren G Einarson A Chun-Fai-Chan B Fayez I Kalra S Voyer-Lavigne S

  • Cite

    Am J Obstet Gynecol. 2005 Mar;192(3):932-6

Hospital admissions for ‘drug-induced’ disorders in England: a study using the Hospital Episodes Statistics (HES) database

  • Author

    Shakir S Waller P Shaw M Ho D Ebrahim S

    Shakir S Waller P Shaw M Ho D Ebrahim S

  • Cite

    Br J Clin Pharmacol. 2005 Feb;59(2):213-9

Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women (multiple letters)

  • Author

    Shakir S Wilton LV Elliott R Kollarova M Heeley E

    Shakir S Wilton LV Elliott R Kollarova M Heeley E

  • Cite

    Drug Saf. 2005;28(6):557; author reply 558

Observational cohort study to monitor the use and safety of carvedilol in the treatment of heart failure in clinical practice in England–1st interim report

  • Author

    Shakir SA Wilton LV Acharya NV

    Shakir SA Wilton LV Acharya NV

  • Cite

    Int J Clin Pharmacol Ther. 2005 Jan;43(1):1-6

A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data

  • Author

    Layton D Shakir SA Kasliwal R Wilton L Harris S

    Layton D Shakir SA Kasliwal R Wilton L Harris S

  • Cite

    Drug Saf. 2005;28(9):803-16

Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study

  • Author

    Layton D Shakir SA Wilton LV

    Layton D Shakir SA Wilton LV

  • Cite

    Eur J Clin Pharmacol. 2004 Sep;60(7):489-501

Re: Layton et al. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data (multiple letters) [12]

  • Author

    Shakir S Layton D Harris S Degner F Lesaffre E Zeidler H

    Shakir S Layton D Harris S Degner F Lesaffre E Zeidler H

  • Cite

    Rheumatology (Oxford). 2004 May;43(5):680-1; author reply 681-2

Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999

  • Author

    Shakir SA Wilton LV Boshier A

    Shakir SA Wilton LV Boshier A

  • Cite

    BJU Int. 2004 Apr;93(6):796-801

Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data

  • Author

    Layton D Shakir SA Heeley E

    Layton D Shakir SA Heeley E

  • Cite

    J Clin Pharm Ther. 2004 Apr;29(2):171-81

Prescription-Event Monitoring (PEM) Study of Sildenafil in England.

  • Author

    Shakir SAW Boshier A

    Shakir SAW Boshier A

  • Cite

    Am J Urol Review. January 2004

Yellow Card and ‘green form’ reporting: when is it necessary?

  • Author

    Shakir SAW Layton D

    Shakir SAW Layton D

  • Cite

    Supplementary Prescribing in Practice. January 2004

Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology

  • Author

    Layton D Shakir SA Clark DW

    Layton D Shakir SA Clark DW

  • Cite

    Drug Saf. 2004;27(7):427-56

Causality and Correlation in Pharmacovigilance

  • Author

    Shakir SAW

    Shakir SAW

  • Cite

    Stephens' Detection of New Adverse Drug Reactions. January 2004

Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000

  • Author

    Shakir SA Wilton LV Boshier A

    Shakir SA Wilton LV Boshier A

  • Cite

    Eur J Clin Pharmacol. 2003 Dec;59(10):767-73